Absci Corp (ABSI)

$6.80 +0.29 (4.45%)
Market Cap 1.06B
Revenue (ttm) 2.80M
Net Income (ttm) -115.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,113.57%
Debt to Equity Ratio 0.00
Volume 4,468,100
Avg Vol 4,871,982
Day's Range N/A - N/A
Shares Out 155.91M
Stochastic %K 65%
Beta 2.44
Analysts Strong Sell
Price Target $9.11

Company Profile

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration...

Industry: Biotechnology
Sector: Healthcare
Phone: 360 949 1041
Address:
18105 SE Mill Plain Boulevard, Vancouver, United States
MAs_Crxss
MAs_Crxss Jun. 13 at 10:26 PM
$ABSI I’m ready for another leg up… you know, whenever you are
0 · Reply
ChipDistribution7
ChipDistribution7 Jun. 12 at 4:05 PM
$ABSI pushing into multi-year highs as the market starts pricing in the AI-drug design narrative getting real traction. The Leerink coverage at Outperform with a $12 target helped anchor sentiment around ABS-201, a prolactin receptor antibody designed with AI that could represent a genuinely new mechanism rather than another incremental biotech iteration. Early Phase 1/2a data suggesting only a few injections over months is what’s catching attention here. Stock already up strong into ~$7 and still seeing follow-through buying. Big picture, this is the AI story bleeding into biotech, but execution and clinical readouts will ultimately decide if this is hype or a platform shift.
0 · Reply
7m3835d3
7m3835d3 Jun. 12 at 2:07 PM
$ABSI lovely. All the people who are selling at this price and then waiting for this to drop below $5 again to re-enter, clearly have no understanding of what Absci is actually working on and why this is so exciting. Looking forward to the safety data release!
0 · Reply
musky54
musky54 Jun. 12 at 2:05 PM
$ABSI what a beauty this stock is
1 · Reply
TT_
TT_ Jun. 10 at 8:41 PM
$ABSI hmm wonder why the run up to only end the day with a big sell off 🤔
1 · Reply
Ericmao
Ericmao Jun. 10 at 2:12 PM
$TEM $SDGR $ABCL $ABSI bullish !!!!
0 · Reply
7m3835d3
7m3835d3 Jun. 10 at 1:33 PM
$ABSI it’s crazy, 3 months ago we were at $2.30. Love this enthusiasm, we are absolutely going in the right direction. If everything goes well, this has the potential to 10x in 2-3 years
0 · Reply
Biotech_Beast
Biotech_Beast Jun. 10 at 2:01 AM
$ABSI A key readout in H2'26 for this name. Although there is competition in alopecia. $MANE https://seekingalpha.com/article/4913490-absci-corporation-a-big-binary-approaching-in-alopecia
1 · Reply
flam70
flam70 Jun. 9 at 11:39 PM
$ABSI can anyone open the slides from goldman presentation? They presented some new data on abs 201 in females for Alopecia. I cant seem to open it
1 · Reply
flam70
flam70 Jun. 9 at 8:50 PM
$ABSI anyone listen to the goldman presentation,?
0 · Reply
Latest News on ABSI
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

Jun 12, 2026, 9:00 AM EDT - 2 days ago

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

HYFT

Absci Slides: FY 2026

Jun 9, 2026, 3:20 PM EDT - 4 days ago

Absci Slides: FY 2026

Absci Transcript: AGM 2026

Jun 4, 2026, 9:00 AM EDT - 10 days ago

Absci Transcript: AGM 2026

Absci initiated with an Outperform at Leerink

2026-06-04T10:38:54.000Z - 10 days ago

Absci initiated with an Outperform at Leerink

Absci Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 7:35 AM EDT - 11 days ago

Absci Transcript: Jefferies Global Healthcare Conference 2026

Absci Slides: FY 2026

Jun 3, 2026, 7:35 AM EDT - 11 days ago

Absci Slides: FY 2026

Absci initiated with a Buy at BTIG

2026-05-28T11:20:41.000Z - 17 days ago

Absci initiated with a Buy at BTIG

Absci to Participate in Upcoming Investor Conferences

May 20, 2026, 8:00 AM EDT - 25 days ago

Absci to Participate in Upcoming Investor Conferences

Absci price target lowered to $4.10 from $4.20 at Morgan Stanley

2026-05-14T17:07:20.000Z - 4 weeks ago

Absci price target lowered to $4.10 from $4.20 at Morgan Stanley

Absci price target raised to $11 from $9 at JonesResearch

2026-05-13T08:40:11.000Z - 4 weeks ago

Absci price target raised to $11 from $9 at JonesResearch

Absci reports Q1 EPS (19c), consensus (20c)

2026-05-07T22:23:30.000Z - 5 weeks ago

Absci reports Q1 EPS (19c), consensus (20c)

Absci Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 5 weeks ago

Absci Earnings Call Transcript: Q1 2026

Absci Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 5 weeks ago

Absci Earnings release: Q1 2026

Absci Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 5 weeks ago

Absci Quarterly report: Q1 2026

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

May 7, 2026, 4:05 PM EDT - 5 weeks ago

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Absci Slides: Corporate presentation

May 7, 2026, 4:00 PM EDT - 5 weeks ago

Absci Slides: Corporate presentation

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026, 8:11 PM EDT - 5 weeks ago

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

Apr 23, 2026, 4:05 PM EDT - 7 weeks ago

Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

Absci Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 7 weeks ago

Absci Proxy statement: Proxy filing

Absci Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 7 weeks ago

Absci Proxy statement: Proxy filing

Absci Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 1:30 PM EDT - 2 months ago

Absci Transcript: 25th Annual Needham Virtual Healthcare Conference

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Absci price target lowered to $4.20 from $4.32 at Morgan Stanley

2026-03-25T11:35:46.000Z - 2 months ago

Absci price target lowered to $4.20 from $4.32 at Morgan Stanley

Absci Earnings Call Transcript: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 2 months ago

Absci Earnings Call Transcript: Q4 2025

Absci Annual report: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 2 months ago

Absci Annual report: Q4 2025

Absci Earnings release: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 2 months ago

Absci Earnings release: Q4 2025

Absci reports Q4 EPS (20c), consensus (17c)

2026-03-24T20:13:40.000Z - 2 months ago

Absci reports Q4 EPS (20c), consensus (17c)

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

Mar 24, 2026, 4:05 PM EDT - 2 months ago

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

Absci Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:00 AM EDT - 3 months ago

Absci Transcript: Leerink Global Healthcare Conference 2026

Absci appoints Ransi Somaratne as CMO

2026-03-03T13:10:19.000Z - 3 months ago

Absci appoints Ransi Somaratne as CMO

VRTX

Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

Mar 3, 2026, 8:00 AM EST - 3 months ago

Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

Absci Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 3 months ago

Absci Transcript: TD Cowen 46th Annual Health Care Conference

Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

Feb 24, 2026, 8:00 AM EST - 3 months ago

Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

AMD discloses positions in Absci, Sanmina

2026-02-17T15:15:21.000Z - 4 months ago

AMD discloses positions in Absci, Sanmina

AMD SANM

Absci Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 5 months ago

Absci Transcript: 44th Annual J.P. Morgan Healthcare Conference

Absci Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 5 months ago

Absci Slides: 44th Annual J.P. Morgan Healthcare Conference

Absci downgraded to Equal Weight from Overweight at Morgan Stanley

2026-01-08T11:15:21.000Z - 5 months ago

Absci downgraded to Equal Weight from Overweight at Morgan Stanley

Absci price target raised to $8 from $7 at H.C. Wainwright

2025-12-17T17:40:17.000Z - 6 months ago

Absci price target raised to $8 from $7 at H.C. Wainwright

Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 16, 2025, 8:00 AM EST - 6 months ago

Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Absci Transcript: Status Update

Dec 11, 2025, 10:00 AM EST - 6 months ago

Absci Transcript: Status Update

Absci Press release: Status Update

Dec 11, 2025, 10:00 AM EST - 6 months ago

Absci Press release: Status Update

Absci Slides: Status Update

Dec 11, 2025, 10:00 AM EST - 6 months ago

Absci Slides: Status Update

Absci’s ABS-201 shows efficacy in hair regeneration

2025-12-11T13:11:11.000Z - 6 months ago

Absci’s ABS-201 shows efficacy in hair regeneration

Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization

Dec 11, 2025, 8:00 AM EST - 6 months ago

Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization

Absci, former U.S. soccer player Donovan announce partnership

2025-12-10T13:05:10.000Z - 6 months ago

Absci, former U.S. soccer player Donovan announce partnership

Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research

Dec 10, 2025, 8:00 AM EST - 6 months ago

Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

Dec 4, 2025, 8:00 AM EST - 6 months ago

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

Absci Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 4:30 AM EST - 7 months ago

Absci Transcript: Jefferies London Healthcare Conference 2025

Absci Slides: FY 2025

Nov 18, 2025, 4:30 AM EST - 7 months ago

Absci Slides: FY 2025

Absci Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Absci Earnings Call Transcript: Q3 2025

Absci Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Absci Quarterly report: Q3 2025

Absci Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Absci Earnings release: Q3 2025

Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

Nov 12, 2025, 4:05 PM EST - 7 months ago

Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

Absci Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 10:00 AM EST - 7 months ago

Absci Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

Oct 29, 2025, 4:05 PM EDT - 8 months ago

Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial

Oct 15, 2025, 8:00 AM EDT - 8 months ago

Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

Sep 11, 2025, 8:00 AM EDT - 9 months ago

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

Absci Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 9:30 AM EDT - 9 months ago

Absci Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Absci Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 3:20 PM EDT - 9 months ago

Absci Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

Aug 25, 2025, 4:05 PM EDT - 10 months ago

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

Absci Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

Absci Earnings Call Transcript: Q2 2025

Absci Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

Absci Quarterly report: Q2 2025

Absci Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

Absci Earnings release: Q2 2025

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

Aug 12, 2025, 4:05 PM EDT - 10 months ago

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

Absci Registration statement: Registration Filing

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Absci Registration statement: Registration Filing

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

Aug 7, 2025, 2:00 AM EDT - 11 months ago

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

Jul 30, 2025, 4:05 PM EDT - 11 months ago

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

Absci Announces Pricing of Public Offering of Common Stock

Jul 24, 2025, 8:45 PM EDT - 11 months ago

Absci Announces Pricing of Public Offering of Common Stock

Absci Announces Proposed Public Offering of Common Stock

Jul 24, 2025, 4:54 PM EDT - 11 months ago

Absci Announces Proposed Public Offering of Common Stock

Absci Appoints Biopharma Leader Mary Szela to Board of Directors

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Absci Appoints Biopharma Leader Mary Szela to Board of Directors

Absci Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 8:40 AM EDT - 1 year ago

Absci Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Absci Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 2:00 PM EDT - 1 year ago

Absci Transcript: Jefferies Global Healthcare Conference 2025

Absci Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Absci Earnings Call Transcript: Q1 2025

Absci Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Absci Earnings release: Q1 2025

Absci Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Absci Quarterly report: Q1 2025

Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

May 13, 2025, 4:05 PM EDT - 1 year ago

Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

May 13, 2025, 4:01 PM EDT - 1 year ago

Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

Absci Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Absci Proxy statement: Proxy Filing

Absci Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Absci Proxy statement: Proxy Filing

Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

Apr 14, 2025, 4:05 PM EDT - 1 year ago

Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

Absci Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 11:45 AM EDT - 1 year ago

Absci Transcript: 24th Annual Needham Virtual Healthcare Conference

Absci Transcript: H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Conference

Apr 2, 2025, 10:30 AM EDT - 1 year ago

Absci Transcript: H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Conference

Absci Registration statement: Registration Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Absci Registration statement: Registration Filing

Absci Transcript: KeyBanc Annual Health Care Forum 2025

Mar 19, 2025, 9:00 AM EDT - 1 year ago

Absci Transcript: KeyBanc Annual Health Care Forum 2025

Absci Slides: FY 2025

Mar 19, 2025, 9:00 AM EDT - 1 year ago

Absci Slides: FY 2025

Absci Earnings Call Transcript: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Absci Earnings Call Transcript: Q4 2024

Absci Annual report: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Absci Annual report: Q4 2024

Absci Earnings release: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Absci Earnings release: Q4 2024

Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

Mar 18, 2025, 4:05 PM EDT - 1 year ago

Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

Mar 4, 2025, 4:05 PM EST - 1 year ago

Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

Mar 4, 2025, 8:00 AM EST - 1 year ago

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

Absci Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 3:10 PM EST - 1 year ago

Absci Transcript: TD Cowen 45th Annual Healthcare Conference

Absci to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 8:00 AM EST - 1 year ago

Absci to Participate in the TD Cowen 45th Annual Health Care Conference

Absci Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 3:00 PM EST - 1 year ago

Absci Transcript: Guggenheim SMID Cap Biotech Conference

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Jan 22, 2025, 8:00 AM EST - 1 year ago

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Absci Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

Absci Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Absci Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

Absci Slides: FY 2025

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

Jan 10, 2025, 7:30 AM EST - 1 year ago

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

Jan 8, 2025, 7:00 AM EST - 1 year ago

Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health

Jan 6, 2025, 8:00 AM EST - 1 year ago

Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health

Absci Transcript: R&D Day 2024

Dec 12, 2024, 9:00 AM EST - 1 year ago

Absci Transcript: R&D Day 2024

Absci Press release: FY 2024

Dec 12, 2024, 9:00 AM EST - 1 year ago

Absci Press release: FY 2024

Absci Slides: FY 2024

Dec 12, 2024, 9:00 AM EST - 1 year ago

Absci Slides: FY 2024

Absci Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 1:50 PM EST - 1 year ago

Absci Transcript: Stifel 2024 Healthcare Conference

Absci Transcript: UBS Global Healthcare Conference

Nov 13, 2024, 10:15 AM EST - 1 year ago

Absci Transcript: UBS Global Healthcare Conference

Absci Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Absci Earnings Call Transcript: Q3 2024

Absci Quarterly report: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Absci Quarterly report: Q3 2024

Absci Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Absci Earnings release: Q3 2024

Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results

Nov 12, 2024, 7:30 AM EST - 1 year ago

Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results

Absci Transcript: Guggenheim Inaugural Global Healthcare Conference

Nov 11, 2024, 10:00 AM EST - 1 year ago

Absci Transcript: Guggenheim Inaugural Global Healthcare Conference

Absci to Host R&D Day on December 12, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Absci to Host R&D Day on December 12, 2024

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

Absci Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 10, 2024, 11:00 AM EDT - 1 year ago

Absci Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Absci Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 5:35 PM EDT - 1 year ago

Absci Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Absci Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Absci Earnings Call Transcript: Q2 2024

Absci Quarterly report: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Absci Quarterly report: Q2 2024

Absci Earnings release: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Absci Earnings release: Q2 2024

Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results

Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI

Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024

Absci Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 2:00 PM EDT - 2 years ago

Absci Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 8:00 AM EDT - 2 years ago

Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Absci Earnings Call Transcript: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

Absci Earnings Call Transcript: Q1 2024

Absci Quarterly report: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

Absci Quarterly report: Q1 2024

Absci Earnings release: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

Absci Earnings release: Q1 2024

Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results

May 14, 2024, 7:30 AM EDT - 2 years ago

Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results

Absci Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Absci Proxy statement: Proxy Filing

Absci Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Absci Proxy statement: Proxy Filing

Absci Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 8, 2024, 3:00 PM EDT - 2 years ago

Absci Transcript: 23rd Annual Needham Virtual Healthcare Conference

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

Mar 21, 2024, 7:30 AM EDT - 2 years ago

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

Absci Annual report: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Absci Annual report: Q4 2023

Absci Earnings release: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Absci Earnings release: Q4 2023

Absci Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 19, 2024, 10:30 AM EDT - 2 years ago

Absci Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Absci Transcript: H.C. Wainwright 1st Annual AI Based Drug Discovery & Development Conference (Virtual)

Mar 7, 2024, 10:30 AM EST - 2 years ago

Absci Transcript: H.C. Wainwright 1st Annual AI Based Drug Discovery & Development Conference (Virtual)

Absci Transcript: KeyBanc’s Emerging Technology Summit

Mar 6, 2024, 12:00 PM EST - 2 years ago

Absci Transcript: KeyBanc’s Emerging Technology Summit

Absci Transcript: TD Cowen 44th Annual Health Care Conference

Mar 4, 2024, 2:10 PM EST - 2 years ago

Absci Transcript: TD Cowen 44th Annual Health Care Conference

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Mar 1, 2024, 4:01 PM EST - 2 years ago

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

Feb 21, 2024, 7:30 AM EST - 2 years ago

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

Absci Transcript: 26th Annual Needham Growth Virtual Conference

Jan 19, 2024, 9:30 AM EST - 2 years ago

Absci Transcript: 26th Annual Needham Growth Virtual Conference

Absci Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 11, 2024, 1:30 PM EST - 2 years ago

Absci Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Absci Slides: FY 2024

Jan 11, 2024, 1:30 PM EST - 2 years ago

Absci Slides: FY 2024

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

Jan 10, 2024, 7:30 AM EST - 2 years ago

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

Absci to Participate in the 26th Annual Needham Growth Conference

Jan 3, 2024, 8:00 AM EST - 2 years ago

Absci to Participate in the 26th Annual Needham Growth Conference

Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 28, 2023, 8:00 AM EST - 2 years ago

Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline

Dec 20, 2023, 7:30 AM EST - 2 years ago

Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline

MAs_Crxss
MAs_Crxss Jun. 13 at 10:26 PM
$ABSI I’m ready for another leg up… you know, whenever you are
0 · Reply
ChipDistribution7
ChipDistribution7 Jun. 12 at 4:05 PM
$ABSI pushing into multi-year highs as the market starts pricing in the AI-drug design narrative getting real traction. The Leerink coverage at Outperform with a $12 target helped anchor sentiment around ABS-201, a prolactin receptor antibody designed with AI that could represent a genuinely new mechanism rather than another incremental biotech iteration. Early Phase 1/2a data suggesting only a few injections over months is what’s catching attention here. Stock already up strong into ~$7 and still seeing follow-through buying. Big picture, this is the AI story bleeding into biotech, but execution and clinical readouts will ultimately decide if this is hype or a platform shift.
0 · Reply
7m3835d3
7m3835d3 Jun. 12 at 2:07 PM
$ABSI lovely. All the people who are selling at this price and then waiting for this to drop below $5 again to re-enter, clearly have no understanding of what Absci is actually working on and why this is so exciting. Looking forward to the safety data release!
0 · Reply
musky54
musky54 Jun. 12 at 2:05 PM
$ABSI what a beauty this stock is
1 · Reply
TT_
TT_ Jun. 10 at 8:41 PM
$ABSI hmm wonder why the run up to only end the day with a big sell off 🤔
1 · Reply
Ericmao
Ericmao Jun. 10 at 2:12 PM
$TEM $SDGR $ABCL $ABSI bullish !!!!
0 · Reply
7m3835d3
7m3835d3 Jun. 10 at 1:33 PM
$ABSI it’s crazy, 3 months ago we were at $2.30. Love this enthusiasm, we are absolutely going in the right direction. If everything goes well, this has the potential to 10x in 2-3 years
0 · Reply
Biotech_Beast
Biotech_Beast Jun. 10 at 2:01 AM
$ABSI A key readout in H2'26 for this name. Although there is competition in alopecia. $MANE https://seekingalpha.com/article/4913490-absci-corporation-a-big-binary-approaching-in-alopecia
1 · Reply
flam70
flam70 Jun. 9 at 11:39 PM
$ABSI can anyone open the slides from goldman presentation? They presented some new data on abs 201 in females for Alopecia. I cant seem to open it
1 · Reply
flam70
flam70 Jun. 9 at 8:50 PM
$ABSI anyone listen to the goldman presentation,?
0 · Reply
WINNINGWEEZER
WINNINGWEEZER Jun. 9 at 8:01 PM
$ABSI upgrades in the morning n we take off....this stock is below the radar and I love it. When it's +18 they'll start flooding in n takes us to +25 in no time💪🏾🍷
0 · Reply
WINNINGWEEZER
WINNINGWEEZER Jun. 9 at 7:58 PM
$ABSI only green stock in my portfolio...you're carrying all the slack today💪🏾🍷
1 · Reply
OptionsMaster7
OptionsMaster7 Jun. 9 at 7:36 PM
$ABSI
0 · Reply
FridayMorningQB
FridayMorningQB Jun. 9 at 7:28 PM
$ABSI usually this drops hard after they talk. We will see?!
0 · Reply
funnyrabbitgoesHPC
funnyrabbitgoesHPC Jun. 9 at 6:57 PM
$ABSI this is going to rip tomo if inf data in favor of the MMs
0 · Reply
MAs_Crxss
MAs_Crxss Jun. 9 at 7:37 AM
$OSCR same reason noones talking about $ABSI
0 · Reply
flam70
flam70 Jun. 8 at 10:04 PM
$ABSI safety data befor goldman sachs conference tomorrow?
0 · Reply
musky54
musky54 Jun. 5 at 5:17 PM
$ABSI good thing we had that big up moved yesterday
0 · Reply
Y007
Y007 Jun. 5 at 4:35 PM
$ABSI $5 please 🙏🏼 lol
1 · Reply
JJfor3
JJfor3 Jun. 5 at 1:29 PM
$ABSI 👀
0 · Reply
SherryDubya
SherryDubya Jun. 5 at 6:22 AM
$ABSI 2026 Jeffries Global Healthcare Conference on 6/3 discussed both alopecia and endometriosis studies, specifically positive results of GRAY haired alopecia rat studies resulting in BLACK hair regrowth. I believe they said the injections were every 3 months and results last up to 4 years. The webcast recording is available on their website under “events and presentations.” It’s worth listening to - link below: https://investors.absci.com/news-and-events/events-and-presentations Looking forward to the next presentation on 6/9.
0 · Reply
Stocks_and_Stacks
Stocks_and_Stacks Jun. 5 at 5:15 AM
🚀 Bulls powering through Thursday June 4 on healthcare rotation, energy moves, and small-cap strength! 🐂📈 First off 😎 who’s all up late studying charts and getting ready for tomorrow? Our group just received two new banger alerts that have serious 100-200% run potential. Eyes sharp 👀 $STI +350%+ – Solidion Technology exploding on massive volume, battery tech/newsflow, and short squeeze action. $INDP +115% – Indaptus Therapeutics surging on positive clinical or biotech updates and high-volume breakout. $VERU +88% – Veru Inc. rocketing higher amid healthcare sector rotation and company-specific catalysts. $FOXX +84% – Foxx Development Holdings climbing on speculative interest and strong momentum. $ABSI +23.6% – Absci Corp lifting on biotech/AI-drug discovery news and sector tailwinds. Solid session stacking wins as the Dow hit fresh records, bulls 🐂 keep that momentum rolling into tomorrow! 💪 #TopMovers #BullMarket #Stocks #BangerAlerts #HealthcareStocks
0 · Reply